MY119896A - Long-acting injection suspensions and a process for their preparation. - Google Patents
Long-acting injection suspensions and a process for their preparation.Info
- Publication number
- MY119896A MY119896A MYPI94003276A MYPI9403276A MY119896A MY 119896 A MY119896 A MY 119896A MY PI94003276 A MYPI94003276 A MY PI94003276A MY PI9403276 A MYPI9403276 A MY PI9403276A MY 119896 A MY119896 A MY 119896A
- Authority
- MY
- Malaysia
- Prior art keywords
- preparation
- long
- injection suspensions
- acting injection
- acting
- Prior art date
Links
- 238000002347 injection Methods 0.000 title 1
- 239000007924 injection Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000725 suspension Substances 0.000 title 1
- UCANQOXFIYWYIX-IDEADWEOSA-N (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid Chemical compound OC(=O)c1cc2ccccc2c(Cc2c(O)c(cc3ccccc23)C(O)=O)c1O.CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O.CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O UCANQOXFIYWYIX-IDEADWEOSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A61K38/105—Bombesin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
POORLY SOLUBLE SALTS OF LHRH ANALOGUES, FOR EXAMPLE CETRORELIX EMBONATE, DISPLAY AN INTRINSIC SUSTAINED RELEASE EFFECT IN THE GRAIN SIZE 5 UM TO 200 UM.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4342092A DE4342092B4 (en) | 1993-12-09 | 1993-12-09 | Long-acting suspension for injection and method of preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY119896A true MY119896A (en) | 2005-08-30 |
Family
ID=35953452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI94003276A MY119896A (en) | 1993-12-09 | 1994-12-08 | Long-acting injection suspensions and a process for their preparation. |
Country Status (6)
| Country | Link |
|---|---|
| KR (1) | KR100344330B1 (en) |
| DE (1) | DE69434553T2 (en) |
| MY (1) | MY119896A (en) |
| SI (1) | SI0732934T1 (en) |
| TW (1) | TW327176B (en) |
| UA (1) | UA44722C2 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4342092A1 (en) * | 1993-12-09 | 1995-06-14 | Asta Medica Ag | Long-acting suspension for injection and method of manufacture |
-
1994
- 1994-11-25 SI SI9430478T patent/SI0732934T1/en unknown
- 1994-11-25 KR KR1019960702947A patent/KR100344330B1/en not_active Expired - Lifetime
- 1994-11-25 DE DE69434553T patent/DE69434553T2/en not_active Expired - Lifetime
- 1994-11-25 UA UA96072646A patent/UA44722C2/en unknown
- 1994-12-08 MY MYPI94003276A patent/MY119896A/en unknown
- 1994-12-21 TW TW083111531A patent/TW327176B/en active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4342092A1 (en) * | 1993-12-09 | 1995-06-14 | Asta Medica Ag | Long-acting suspension for injection and method of manufacture |
Also Published As
| Publication number | Publication date |
|---|---|
| TW327176B (en) | 1998-02-21 |
| DE69434553T2 (en) | 2006-08-10 |
| DE69434553D1 (en) | 2005-12-29 |
| KR100344330B1 (en) | 2002-11-30 |
| UA44722C2 (en) | 2002-03-15 |
| KR960706353A (en) | 1996-12-09 |
| SI0732934T1 (en) | 2006-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP940978A2 (en) | Long-acting injection suspensions and a process for their preparation | |
| CA2178592A1 (en) | Long-acting injection suspensions and a process for their preparation | |
| PL325825A1 (en) | Microemulsion for use as a carrier for administering active compounds | |
| EP2016950A8 (en) | Pharmaceutical composition comprising an exendin-4 peptide | |
| GR3026338T3 (en) | High release solid preparation, preparation and use thereof | |
| GB8922026D0 (en) | Novel anti-viral and cytotoxic agent | |
| CA2203033A1 (en) | Compounds and compositions for delivering active agents | |
| AU8418891A (en) | Novel polyamines and method for preparation thereof | |
| CA2354034A1 (en) | Compositions containing a peptide and polylactic-glycolic acid suitable for preparing subcutaneous implants with an extended release period | |
| HUT74270A (en) | Aqueous pharmaceutical preparations of g-csf with a long shelf life and process to prepare them | |
| WO1998017319A3 (en) | Platelet substitutes and conjugation methods suitable for their preparation | |
| IE882671L (en) | Stabilised human protein formulation | |
| AU1179795A (en) | Improved immunogenic compositions against human gastrin 17 | |
| MY106528A (en) | Method of treating impotence. | |
| MX9710206A (en) | Pharmaceutical amiodarone composition for parenteral delivery. | |
| EP0909562A4 (en) | Injections containing lipid a analogues and process for the preparation thereof | |
| IL79816A (en) | Pharmaceutical compositions comprising a drug-polymer matrix | |
| CA2072797A1 (en) | Use of tri (n-butyl) phosphate at low ph in solutions of biologically active proteins for enhanced virucidal activity | |
| CA2273272A1 (en) | Immediate release drug delivery forms | |
| BG102514A (en) | New lh-rh-antagonists of improved effect | |
| MY105110A (en) | Low molecular weight derivatives of prourokinase and pharmaceutical compositions containing the same | |
| IE890275L (en) | Pharmaceutical composition for 4-aroylimidazol-2-ones | |
| GB2292887A (en) | Drug delivery system | |
| CA2021282A1 (en) | Dispenser comprising ionophore | |
| CA2084919A1 (en) | Sustained release tablets |